Vitamin B3 five-year diabetes prevention trial enrollment near completion.
This article was originally published in The Tan Sheet
Executive Summary
VITAMIN B3 FIVE-YEAR, MULTI-CENTER DIABETES MELLITUS TRIAL has nearly completed enrollment. The Canadian/European Niacinamide Diabetes Intervention Trial (CAN ENDIT) will test the effectiveness of niacinamide, a derivative of vitamin B3, in delaying the onset of Type I diabetes in approximately 500 subjects at high risk for the disease.